Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
作者信息
Cramer Yoninah S, Rosenkranz Susan L, Hall Stephen D, Szczech Lynda A, Amorosa Valerianna, Gupta Samir K
出版信息
J Acquir Immune Defic Syndr. 2010 Aug;54(4):e7-9. doi: 10.1097/QAI.0b013e3181e2d5e5.
Abstract
摘要
相似文献
1
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
J Acquir Immune Defic Syndr. 2010 Aug;54(4):e7-9. doi: 10.1097/QAI.0b013e3181e2d5e5.
2
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
J Antimicrob Chemother. 2000 May;45(5):716-7. doi: 10.1093/jac/45.5.716.
3
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
J Infect Dis. 1999 May;179(5):1116-23. doi: 10.1086/314703.
4
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00839-19. Print 2019 Oct.
5
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
J Infect Dis. 1998 Aug;178(2):368-74. doi: 10.1086/515641.
6
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
J Infect Dis. 2001 Jul 1;184(1):37-42. doi: 10.1086/320998. Epub 2001 May 30.
7
Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
Pharmacogenomics. 2021 Sep;22(14):881-884. doi: 10.2217/pgs-2021-0106. Epub 2021 Sep 10.
8
Antiretroviral drug removal by haemodialysis.
AIDS. 2000 May 5;14(7):902-3. doi: 10.1097/00002030-200005050-00022.
9
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
AAPS PharmSci. 2000;2(1):E1. doi: 10.1208/ps020101.
10
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
Nephrol Dial Transplant. 2001 Mar;16(3):643. doi: 10.1093/ndt/16.3.643.
引用本文的文献
1
PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability.
AAPS J. 2025 Mar 12;27(2):59. doi: 10.1208/s12248-025-01042-9.
2
Pharmacotherapeutic options for kidney disease in HIV positive patients.
Expert Opin Pharmacother. 2021 Jan;22(1):69-82. doi: 10.1080/14656566.2020.1817383. Epub 2020 Sep 21.
3
Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.
Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):559-572. doi: 10.1007/s13318-016-0394-6.
4
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
Clin Pharmacokinet. 2017 May;56(5):537-550. doi: 10.1007/s40262-016-0457-5.
5
The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.
P T. 2011 Jun;36(6):346-64.
本文引用的文献
1
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
AIDS. 2008 Oct 1;22(15):1919-27. doi: 10.1097/QAD.0b013e32830e011f.
2
Pharmacokinetic of nevirapine in haemodialysis.
Nephrol Dial Transplant. 2001 Jan;16(1):192-3. doi: 10.1093/ndt/16.1.192.
3
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
J Infect Dis. 1999 May;179(5):1116-23. doi: 10.1086/314703.
Zotero 插件